Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

APGEAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ722.18+ 1.40%S&P 500 · SPY769.66+ 0.56%Dow Jones · DIA523.28+ 0.06%Russell 2000 · IWM280.18+ 1.15%

Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135
Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.
Benzinga07:462 Months AgoAPGE

02:00-09:00Aug 122 Stories

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Benzinga08:18APGE
BTIG Downgrades Apogee Therapeutics to Neutral
BTIG analyst Julian Harrison downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral.
Benzinga02:29APGE

03:00Aug 101 Story

Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share
Benzinga03:22APGE

16:00Aug 71 Story

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...
Yahoo16:14APGE

08:00Aug 51 Story

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Yahoo08:17APGE

10:00-16:00Aug 42 Stories

Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th
Yahoo15:44
Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats
Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph
Yahoo10:56